Feb 28 2011
Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX-V:NTB) and Acasti Pharma ("Acasti"), a Neptune subsidiary, announces that Acasti has received conditional approval for the listing of its class A common shares (the "Class A shares") on the TSX Venture Exchange (the "Exchange") under the ticker symbol APO.
Acasti has received conditional approval from the Exchange for the listing of its Class A share on the TSX-Venture (the "Listing"). The Listing is conditional, to fulfilment by Acasti of all Exchange's requirements including, among others: (i) the conversion of all outstanding Class B and Class C preferred shares into Class A shares on a 1:1 basis, (ii) the signature of an escrow agreement between Acasti, the escrow agent and Acasti's principal securities holders, (iii) the filing of amended and restated financial statements for the three and nine-month periods ended November 30th, 2010 reflecting, among others, subsequent events in connection with the Listing, and (iv) the completion of satisfactory background searches on Acasti's insiders.
Acasti's management expects to waive all conditions with respect to the Listing prior to March 21, 2011. A complete press release will be issued by Acasti and Neptune at the time of the Listing, providing summary disclosure of the Listing and any related transaction.
Source:
Neptune Technologies & Bioressources Inc.